Roidipedia.Compound reference & reporting
05 AUG 2026
CompoundsAnabolic steroid Methylstenbolone (Designer Variant)
Anabolic steroidAndrogenDHT-derivedOralDesigner steroid17-alkylated

Methylstenbolone (Designer Variant)

Also known as M-Sten · 2,17α-Dimethyl-5α-androsta-1-en-17β-ol-3-one

A 2,17α-dimethyl DHT-derived designer oral (2,17α-dimethyl-5α-androsta-1-en-17β-ol-3-one) that appeared in pro-hormone supplements alongside dymethazine. Non-aromatising and strongly hepatotoxic; implicated in a published case of cholestatic jaundice.

01 Overview

Methylstenbolone is a methylated relative of stenbolone: a 2,17α-dimethyl-5α-androst-1-ene-3-one structure. It surfaced in "designer" oral supplements in the early 2010s and, like dymethazine, was found in the "Super DMZ" product line that drove FDA action and a documented liver-injury case. This entry covers the grey-market variant as sold, distinct from the base methylstenbolone chemistry.

Being 5α-based and non-aromatising, it produces "dry" gains, but the twin methyl substitutions make it markedly hepatotoxic and strongly suppressive. Human data are limited to marketing anecdote and adverse-event reports.

02 Mechanism

Androgen receptor agonist; 17α-methylation gives oral bioavailability, the 2-methyl and Δ1 features resist metabolism and prevent aromatisation, so effects are purely androgenic/anabolic with no estrogen conversion.

03 Dosing

TierDoseRouteNotes
Label / anecdotal8–16 mg/dayOralFrom former product labels; no clinical basis.

Ester comparison

EsterHalf-lifeInjection freq.Testosterone by mass

04 Effects

EffectMagnitudeEvidence
Dry strength and lean massAnecdotal rapid strength and hardness with minimal water retention.UnquantifiedAnecdotal
No aromatisationStructure cannot aromatise, avoiding estrogenic bloat and gynecomastia.Non-estrogenicPreclinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Cholestatic hepatotoxicityNamed alongside dymethazine in a cholestatic-jaundice case report.SevereCommonObservational
Severe HDL suppressionDry non-aromatising orals sharply lower HDL cholesterol.ModerateVery commonAnecdotal

07 References

Synthetic Androgens as Designer SupplementsCurrent Neuropharmacology / PMC4462045, 2015

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.